The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antitumor Peptide Drugs Market Research Report 2025
Synopsis
The global market for Antitumor Peptide Drugs was valued at US$ 6735 million in the year 2024 and is projected to reach a revised size of US$ 14430 million by 2031, growing at a CAGR of 11.7% during the forecast period.
Antitumor peptide drugs are a class of innovative cancer therapeutics designed based on short-chain amino acid sequences. These peptide drugs exert their antitumor effects through various mechanisms, including inhibiting cancer cell proliferation, inducing apoptosis, disrupting tumor angiogenesis, and enhancing the body's immune response against cancer. Compared to traditional chemotherapy drugs, peptide-based therapies typically offer higher specificity, lower toxicity, and better biocompatibility. Moreover, due to their relatively simple structure, peptides are easier to synthesize and modify, making them a popular area of research in cancer treatment. Currently, some antitumor peptide drugs have entered clinical application, such as LHRH (luteinizing hormone-releasing hormone) analogs, cell-penetrating peptides (CPPs), and antimicrobial peptide (AMP)-based anticancer agents, offering new hope for cancer therapy.
North American market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Antitumor Peptide Drugs include Ipsen, Novartis, AstraZeneca, AbbVie, Ferring Pharmaceuticals, Tolmar, Foresee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antitumor Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antitumor Peptide Drugs.
The Antitumor Peptide Drugs market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antitumor Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antitumor Peptide Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Ipsen
Novartis
AstraZeneca
AbbVie
Ferring Pharmaceuticals
Tolmar
Foresee Pharmaceuticals
Segment by Type
Lanreotide
Octreotide
Goserelin
Leuprolide
Degarelix
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antitumor Peptide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antitumor Peptide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Antitumor Peptide Drugs was valued at US$ 6735 million in the year 2024 and is projected to reach a revised size of US$ 14430 million by 2031, growing at a CAGR of 11.7% during the forecast period.
Antitumor peptide drugs are a class of innovative cancer therapeutics designed based on short-chain amino acid sequences. These peptide drugs exert their antitumor effects through various mechanisms, including inhibiting cancer cell proliferation, inducing apoptosis, disrupting tumor angiogenesis, and enhancing the body's immune response against cancer. Compared to traditional chemotherapy drugs, peptide-based therapies typically offer higher specificity, lower toxicity, and better biocompatibility. Moreover, due to their relatively simple structure, peptides are easier to synthesize and modify, making them a popular area of research in cancer treatment. Currently, some antitumor peptide drugs have entered clinical application, such as LHRH (luteinizing hormone-releasing hormone) analogs, cell-penetrating peptides (CPPs), and antimicrobial peptide (AMP)-based anticancer agents, offering new hope for cancer therapy.
North American market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Antitumor Peptide Drugs include Ipsen, Novartis, AstraZeneca, AbbVie, Ferring Pharmaceuticals, Tolmar, Foresee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antitumor Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antitumor Peptide Drugs.
The Antitumor Peptide Drugs market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antitumor Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antitumor Peptide Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Ipsen
Novartis
AstraZeneca
AbbVie
Ferring Pharmaceuticals
Tolmar
Foresee Pharmaceuticals
Segment by Type
Lanreotide
Octreotide
Goserelin
Leuprolide
Degarelix
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antitumor Peptide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antitumor Peptide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antitumor Peptide Drugs Market Overview
1.1 Product Definition
1.2 Antitumor Peptide Drugs by Type
1.2.1 Global Antitumor Peptide Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Lanreotide
1.2.3 Octreotide
1.2.4 Goserelin
1.2.5 Leuprolide
1.2.6 Degarelix
1.3 Antitumor Peptide Drugs by Application
1.3.1 Global Antitumor Peptide Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Antitumor Peptide Drugs Market Size Estimates and Forecasts
1.4.1 Global Antitumor Peptide Drugs Revenue 2020-2031
1.4.2 Global Antitumor Peptide Drugs Sales 2020-2031
1.4.3 Global Antitumor Peptide Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antitumor Peptide Drugs Market Competition by Manufacturers
2.1 Global Antitumor Peptide Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Antitumor Peptide Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Antitumor Peptide Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antitumor Peptide Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antitumor Peptide Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antitumor Peptide Drugs, Product Type & Application
2.7 Global Key Manufacturers of Antitumor Peptide Drugs, Date of Enter into This Industry
2.8 Global Antitumor Peptide Drugs Market Competitive Situation and Trends
2.8.1 Global Antitumor Peptide Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antitumor Peptide Drugs Players Market Share by Revenue
2.8.3 Global Antitumor Peptide Drugs Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antitumor Peptide Drugs Market Scenario by Region
3.1 Global Antitumor Peptide Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antitumor Peptide Drugs Sales by Region: 2020-2031
3.2.1 Global Antitumor Peptide Drugs Sales by Region: 2020-2025
3.2.2 Global Antitumor Peptide Drugs Sales by Region: 2026-2031
3.3 Global Antitumor Peptide Drugs Revenue by Region: 2020-2031
3.3.1 Global Antitumor Peptide Drugs Revenue by Region: 2020-2025
3.3.2 Global Antitumor Peptide Drugs Revenue by Region: 2026-2031
3.4 North America Antitumor Peptide Drugs Market Facts & Figures by Country
3.4.1 North America Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antitumor Peptide Drugs Sales by Country (2020-2031)
3.4.3 North America Antitumor Peptide Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antitumor Peptide Drugs Market Facts & Figures by Country
3.5.1 Europe Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antitumor Peptide Drugs Sales by Country (2020-2031)
3.5.3 Europe Antitumor Peptide Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antitumor Peptide Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Antitumor Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antitumor Peptide Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Antitumor Peptide Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antitumor Peptide Drugs Market Facts & Figures by Country
3.7.1 Latin America Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antitumor Peptide Drugs Sales by Country (2020-2031)
3.7.3 Latin America Antitumor Peptide Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antitumor Peptide Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antitumor Peptide Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antitumor Peptide Drugs Sales by Type (2020-2031)
4.1.1 Global Antitumor Peptide Drugs Sales by Type (2020-2025)
4.1.2 Global Antitumor Peptide Drugs Sales by Type (2026-2031)
4.1.3 Global Antitumor Peptide Drugs Sales Market Share by Type (2020-2031)
4.2 Global Antitumor Peptide Drugs Revenue by Type (2020-2031)
4.2.1 Global Antitumor Peptide Drugs Revenue by Type (2020-2025)
4.2.2 Global Antitumor Peptide Drugs Revenue by Type (2026-2031)
4.2.3 Global Antitumor Peptide Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Antitumor Peptide Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Antitumor Peptide Drugs Sales by Application (2020-2031)
5.1.1 Global Antitumor Peptide Drugs Sales by Application (2020-2025)
5.1.2 Global Antitumor Peptide Drugs Sales by Application (2026-2031)
5.1.3 Global Antitumor Peptide Drugs Sales Market Share by Application (2020-2031)
5.2 Global Antitumor Peptide Drugs Revenue by Application (2020-2031)
5.2.1 Global Antitumor Peptide Drugs Revenue by Application (2020-2025)
5.2.2 Global Antitumor Peptide Drugs Revenue by Application (2026-2031)
5.2.3 Global Antitumor Peptide Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Antitumor Peptide Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Ipsen
6.1.1 Ipsen Company Information
6.1.2 Ipsen Description and Business Overview
6.1.3 Ipsen Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Ipsen Antitumor Peptide Drugs Product Portfolio
6.1.5 Ipsen Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Novartis Antitumor Peptide Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Antitumor Peptide Drugs Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AbbVie Antitumor Peptide Drugs Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Ferring Pharmaceuticals
6.5.1 Ferring Pharmaceuticals Company Information
6.5.2 Ferring Pharmaceuticals Description and Business Overview
6.5.3 Ferring Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ferring Pharmaceuticals Antitumor Peptide Drugs Product Portfolio
6.5.5 Ferring Pharmaceuticals Recent Developments/Updates
6.6 Tolmar
6.6.1 Tolmar Company Information
6.6.2 Tolmar Description and Business Overview
6.6.3 Tolmar Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Tolmar Antitumor Peptide Drugs Product Portfolio
6.6.5 Tolmar Recent Developments/Updates
6.7 Foresee Pharmaceuticals
6.7.1 Foresee Pharmaceuticals Company Information
6.7.2 Foresee Pharmaceuticals Description and Business Overview
6.7.3 Foresee Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Foresee Pharmaceuticals Antitumor Peptide Drugs Product Portfolio
6.7.5 Foresee Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antitumor Peptide Drugs Industry Chain Analysis
7.2 Antitumor Peptide Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antitumor Peptide Drugs Production Mode & Process Analysis
7.4 Antitumor Peptide Drugs Sales and Marketing
7.4.1 Antitumor Peptide Drugs Sales Channels
7.4.2 Antitumor Peptide Drugs Distributors
7.5 Antitumor Peptide Drugs Customer Analysis
8 Antitumor Peptide Drugs Market Dynamics
8.1 Antitumor Peptide Drugs Industry Trends
8.2 Antitumor Peptide Drugs Market Drivers
8.3 Antitumor Peptide Drugs Market Challenges
8.4 Antitumor Peptide Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Antitumor Peptide Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Antitumor Peptide Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Antitumor Peptide Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Antitumor Peptide Drugs Sales (kg) of Key Manufacturers (2020-2025)
Table 5. Global Antitumor Peptide Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Antitumor Peptide Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Antitumor Peptide Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Antitumor Peptide Drugs Average Price (US$/g) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Antitumor Peptide Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Antitumor Peptide Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antitumor Peptide Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Antitumor Peptide Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antitumor Peptide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antitumor Peptide Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antitumor Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Antitumor Peptide Drugs Sales by Region (2020-2025) & (kg)
Table 18. Global Antitumor Peptide Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Antitumor Peptide Drugs Sales by Region (2026-2031) & (kg)
Table 20. Global Antitumor Peptide Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Antitumor Peptide Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Antitumor Peptide Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Antitumor Peptide Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Antitumor Peptide Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)
Table 27. North America Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)
Table 28. North America Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)
Table 32. Europe Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)
Table 33. Europe Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Antitumor Peptide Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Antitumor Peptide Drugs Sales by Region (2020-2025) & (kg)
Table 37. Asia Pacific Antitumor Peptide Drugs Sales by Region (2026-2031) & (kg)
Table 38. Asia Pacific Antitumor Peptide Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Antitumor Peptide Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)
Table 42. Latin America Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)
Table 43. Latin America Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)
Table 47. Middle East and Africa Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)
Table 48. Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Antitumor Peptide Drugs Sales (kg) by Type (2020-2025)
Table 51. Global Antitumor Peptide Drugs Sales (kg) by Type (2026-2031)
Table 52. Global Antitumor Peptide Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Antitumor Peptide Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Antitumor Peptide Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Antitumor Peptide Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Antitumor Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Antitumor Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Antitumor Peptide Drugs Price (US$/g) by Type (2020-2025)
Table 59. Global Antitumor Peptide Drugs Price (US$/g) by Type (2026-2031)
Table 60. Global Antitumor Peptide Drugs Sales (kg) by Application (2020-2025)
Table 61. Global Antitumor Peptide Drugs Sales (kg) by Application (2026-2031)
Table 62. Global Antitumor Peptide Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Antitumor Peptide Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Antitumor Peptide Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Antitumor Peptide Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Antitumor Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Antitumor Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Antitumor Peptide Drugs Price (US$/g) by Application (2020-2025)
Table 69. Global Antitumor Peptide Drugs Price (US$/g) by Application (2026-2031)
Table 70. Ipsen Company Information
Table 71. Ipsen Description and Business Overview
Table 72. Ipsen Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 73. Ipsen Antitumor Peptide Drugs Product
Table 74. Ipsen Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 78. Novartis Antitumor Peptide Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. AstraZeneca Company Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 83. AstraZeneca Antitumor Peptide Drugs Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. AbbVie Company Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 88. AbbVie Antitumor Peptide Drugs Product
Table 89. AbbVie Recent Developments/Updates
Table 90. Ferring Pharmaceuticals Company Information
Table 91. Ferring Pharmaceuticals Description and Business Overview
Table 92. Ferring Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 93. Ferring Pharmaceuticals Antitumor Peptide Drugs Product
Table 94. Ferring Pharmaceuticals Recent Developments/Updates
Table 95. Tolmar Company Information
Table 96. Tolmar Description and Business Overview
Table 97. Tolmar Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 98. Tolmar Antitumor Peptide Drugs Product
Table 99. Tolmar Recent Developments/Updates
Table 100. Foresee Pharmaceuticals Company Information
Table 101. Foresee Pharmaceuticals Description and Business Overview
Table 102. Foresee Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 103. Foresee Pharmaceuticals Antitumor Peptide Drugs Product
Table 104. Foresee Pharmaceuticals Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Antitumor Peptide Drugs Distributors List
Table 108. Antitumor Peptide Drugs Customers List
Table 109. Antitumor Peptide Drugs Market Trends
Table 110. Antitumor Peptide Drugs Market Drivers
Table 111. Antitumor Peptide Drugs Market Challenges
Table 112. Antitumor Peptide Drugs Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antitumor Peptide Drugs
Figure 2. Global Antitumor Peptide Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antitumor Peptide Drugs Market Share by Type: 2024 & 2031
Figure 4. Lanreotide Product Picture
Figure 5. Octreotide Product Picture
Figure 6. Goserelin Product Picture
Figure 7. Leuprolide Product Picture
Figure 8. Degarelix Product Picture
Figure 9. Global Antitumor Peptide Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Antitumor Peptide Drugs Market Share by Application: 2024 & 2031
Figure 11. Hospital
Figure 12. Clinic
Figure 13. Others
Figure 14. Global Antitumor Peptide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Antitumor Peptide Drugs Market Size (2020-2031) & (US$ Million)
Figure 16. Global Antitumor Peptide Drugs Sales (2020-2031) & (kg)
Figure 17. Global Antitumor Peptide Drugs Average Price (US$/g) & (2020-2031)
Figure 18. Antitumor Peptide Drugs Report Years Considered
Figure 19. Antitumor Peptide Drugs Sales Share by Manufacturers in 2024
Figure 20. Global Antitumor Peptide Drugs Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Antitumor Peptide Drugs Players: Market Share by Revenue in Antitumor Peptide Drugs in 2024
Figure 22. Antitumor Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Antitumor Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)
Figure 25. North America Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)
Figure 26. United States Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)
Figure 29. Europe Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)
Figure 30. Germany Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Antitumor Peptide Drugs Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Antitumor Peptide Drugs Revenue Market Share by Region (2020-2031)
Figure 37. China Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)
Figure 45. Latin America Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Antitumor Peptide Drugs by Type (2020-2031)
Figure 56. Global Revenue Market Share of Antitumor Peptide Drugs by Type (2020-2031)
Figure 57. Global Antitumor Peptide Drugs Price (US$/g) by Type (2020-2031)
Figure 58. Global Sales Market Share of Antitumor Peptide Drugs by Application (2020-2031)
Figure 59. Global Revenue Market Share of Antitumor Peptide Drugs by Application (2020-2031)
Figure 60. Global Antitumor Peptide Drugs Price (US$/g) by Application (2020-2031)
Figure 61. Antitumor Peptide Drugs Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
